Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, pasireotide (Signifor®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. |
||
|
||
Medicine details |
||
| Medicine name | pasireotide pamoate (Signifor®) | |
| Formulation | 10 mg powder and solvent for suspension for injection, 20 mg powder and solvent for suspension for injection, 30 mg powder and solvent for suspension for injection, 40 mg powder and solvent for suspension for injection, 60 mg powder and solvent for suspension for injection | |
| Reference number | 1726 | |
| Indication | For the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 08/12/2017 | |
| Date of issue | 12/12/2017 | |